Role of P2X7 purinoceptors in neuroprotective mechanism of ischemic postconditioning in mice

被引:14
作者
Bindra, Chanpreet Singh [1 ]
Jaggi, Amteshwar Singh [1 ]
Singh, Nirmal [1 ]
机构
[1] Punjabi Univ, Fac Med, Dept Pharmaceut Sci & Drug Res, Div Pharmacol, Patiala 147002, Punjab, India
关键词
Ischemic postconditioning; Cerebral Ischemia; Purinergic P2X7 receptor; Ischemia-reperfusion injury; Brilliant Blue G; Neuroprotection in mice; FOCAL CEREBRAL-ISCHEMIA; REPERFUSION INJURY; TRIPHENYLTETRAZOLIUM CHLORIDE; BEHAVIORAL DEFICITS; MOUSE MODEL; RECEPTOR; ADENOSINE; ACTIVATION; PATHOPHYSIOLOGY; ATTENUATION;
D O I
10.1007/s11010-014-1967-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cerebral ischemia-reperfusion (I-R) injury is one of the primary causes of ischemic stroke. Ischemic postconditioning (iPoCo) is evolving as an important adaptive technique to contain I-R injury. Some recent studies have shown neuroprotective effect of iPoCo. However, neuroprotective mechanism of iPoCo is not clear. So, the present study has been undertaken to investigate the possible role of P2X7 purinoceptors in neuroprotective mechanism of iPoCo in mice. Bilateral carotid artery occlusion for 12 min followed by R for 24 h produced a significant rise in cerebral infarct size and neurological severity score (NSS) along with impairment of memory and motor coordination. iPoCo, involving three episodes of 10-s carotid artery occlusion with intermittent R of 10 s applied just after ischemic insult of 12 min, produced a significant decrease in cerebral infarct size and NSS along with reversal of I-R-induced impairment of memory and motor coordination. iPoCo induced neuroprotective effects were significantly abolished by pretreatment with selective purinergic P2X7 receptor blocker Brilliant Blue G (40 mg/kg intraperitoneal). It may be concluded that neuroprotective effect of iPoCo probably involves in activation of purinergic P2X7 receptors.
引用
收藏
页码:161 / 173
页数:13
相关论文
共 73 条
[1]   International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy [J].
Abbracchio, Maria P. ;
Burnstock, Geoffrey ;
Boeynaems, Jean-Marie ;
Barnard, Eric A. ;
Boyer, Jose L. ;
Kennedy, Charles ;
Knight, Gillian E. ;
Fumagalli, Marta ;
Gachet, Christian ;
Jacobson, Kenneth A. ;
Weisman, Gary A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :281-341
[2]   PURINOCEPTORS - ARE THERE FAMILIES OF P2X AND P2Y PURINOCEPTORS [J].
ABBRACCHIO, MP ;
BURNSTOCK, G .
PHARMACOLOGY & THERAPEUTICS, 1994, 64 (03) :445-475
[3]  
[Anonymous], WORKSH REP STROK SUR
[4]  
[Anonymous], 2010, STROK CER ACC
[5]  
BEUTLER E, 1963, J LAB CLIN MED, V61, P882
[6]  
Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653
[7]   Modulators of Nucleoside Metabolism in the Therapy of Brain Diseases [J].
Boison, Detlev .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (08) :1068-1086
[8]   IS THERE A BASIS FOR DISTINGUISHING 2 TYPES OF P2-PURINOCEPTOR [J].
BURNSTOCK, G ;
KENNEDY, C .
GENERAL PHARMACOLOGY, 1985, 16 (05) :433-440
[9]  
Burnstock G., 1978, CELL MEMBRAIN RECEPT, P107, DOI DOI 10.1016/0014-5793(79)81367-8
[10]   Physiology and pathophysiology of purinergic neurotransmission [J].
Burnstock, Geoffrey .
PHYSIOLOGICAL REVIEWS, 2007, 87 (02) :659-797